Anti-aging composition having immune function enhancing effect, and functional food containing the same

Abstract

To provide a novel anti-aging composition composed of food materials.SOLUTION: An anti-aging composition comprises liposomes encapsulating saccharides, wherein the saccharides comprises 0.1-6.75 pts.mass of galactose, 1-15 pts.mass of xylose, 0.3-16.5 pts.mass of glucose, 0.05-0.75 pt.mass of N-acetylgalactosamine, 0.1-1.5 pts.mass of N-acetylglucosamine, 0.1-0.75 pt.mass of mannose, 0.01-0.45 pt.mass of fucose, and 0.005-0.15 pt.mass of N-acetylneuraminic acid, and the anti-aging composition exhibits an immune function enhancing effect.SELECTED DRAWING: Figure 1

Description

[Technical field]

[0001] The present invention relates to an anti-aging composition having an immune function improving effect and a functional food containing said composition. [Background technology]

[0002] 2. Description of the Related Art Beauty has always been a concern for many people, and therefore, various compositions have been proposed as being beneficial for beauty.

[0003] For example, compositions having anti-aging properties are useful for providing radiance and firmness to the skin, thus maintaining a youthful appearance.

[0004] Among such anti-aging compositions, there are also compositions in which the components for inducing anti-aging effects are realized using materials that can be ingested as food, such as carrots (see, for example, Patent Document 1).

[0005] A composition having an anti-aging effect composed of such food ingredients can prevent aging through daily eating habits, and is useful as one of the lifestyle habits that contribute to beauty. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2022-534014 Summary of the Invention [Problem to be solved by the invention]

[0007] However, market needs for such anti-aging compositions are expected to continue to increase in the future, and further variations are required to allow consumers to select according to their preferences.

[0008] In addition, as people age, the decline in immune function becomes an issue more and more often. Therefore, if a composition could be provided that could improve immune function while also providing beauty benefits, such a product would have even higher added value.

[0009] The present invention has been made in consideration of the above circumstances, and provides a new anti-aging composition which is composed of food materials and can also improve immune function.

[0010] The present invention also provides functional foods containing such anti-aging compositions having an immune function improving effect. [Means for solving the problem]

[0011] In order to solve the above-mentioned problems, the anti-aging composition of the present invention provides: (1) an anti-aging composition comprising liposomes encapsulating saccharides, the saccharides including 0.1 to 6.75 parts by mass of galactose, 1 to 15 parts by mass of xylose, 0.3 to 16.5 parts by mass of glucose, 0.05 to 0.75 parts by mass of N-acetylgalactosamine, 0.1 to 1.5 parts by mass of N-acetylglucosamine, 0.1 to 0.75 parts by mass of mannose, 0.01 to 0.45 parts by mass of fucose, and 0.005 to 0.15 parts by mass of N-acetylneuraminic acid, and having an immune function improving effect.

[0012] Furthermore, the functional food according to the present invention contains the anti-aging composition described in (2)(1) in an amount of 1.665 to 91.85 parts by mass per 100 parts by mass. Effect of the Invention

[0013] According to the anti-aging composition of the present invention, the anti-aging composition comprises liposomes encapsulating saccharides, the saccharides comprising 0.1 to 6.75 parts by mass of galactose, 1 to 15 parts by mass of xylose, 0.3 to 16.5 parts by mass of glucose, 0.05 to 0.75 parts by mass of N-acetylgalactosamine, 0.1 to 1.5 parts by mass of N-acetylglucosamine, 0.1 to 0.75 parts by mass of mannose, 0.01 to 0.45 parts by mass of fucose, and 0.005 to 0.15 parts by mass of N-acetylneuraminic acid, and has an immune function improving effect. Therefore, a new anti-aging composition can be provided which is composed of food materials and can also improve immune function.

[0014] Furthermore, the functional food of the present invention contains 1.665 to 91.85 parts by mass of the anti-aging composition of the present invention per 100 parts by mass, thereby making it possible to prevent aging through daily eating habits and providing a functional food that is useful as a lifestyle habit that contributes to beauty. [Brief description of the drawings]

[0015] [Figure 1] 1 is a graph showing the results of a test to evaluate inhibition of SA-β-gal activity. [Diagram 2] 1 is a graph showing the results of a test to evaluate inhibition of SA-β-gal activity. [Diagram 3] 1 is a graph showing the results of a test evaluating the expression of aging-related genes. [Figure 4] 1 is a graph showing the results of a test to evaluate intracellular NAD+ amount. [Diagram 5] 1 is a graph showing the results of a test for evaluating intracellular ATP levels. [Figure 6] 1 is a graph showing the results of a macrophage phagocytic activity test. [Figure 7] 1 is a graph showing the results of a test evaluating the effect of an anti-aging composition on anti-inflammatory induced macrophages. [Figure 8] 1 is a graph showing the results of a test evaluating the inhibition of SA-β-gal activity by a comparative composition lacking any one of the saccharides. [Figure 9] FIG. 2 is an explanatory diagram showing the saccharide composition of each test sample in the dose-effect confirmation test. [Figure 10] FIG. 1 is an explanatory diagram showing the details and schedule of a dose-effect confirmation test. [Figure 11] FIG. 1 is an explanatory diagram showing the results of a dose-effect confirmation test. [Figure 12] FIG. 1 is an explanatory diagram showing the results of a dose-effect confirmation test. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] The present invention provides a novel anti-aging composition comprising a liposome encapsulating a saccharide, which is made from a food ingredient and can also improve immune function.

[0017] The phospholipid constituting the liposome is not particularly limited, but for example, lecithin can be suitably used.

[0018] The saccharides to be encapsulated in the liposomes include at least 0.1 to 6.75 parts by mass of galactose, 1 to 15 parts by mass of xylose, 0.3 to 16.5 parts by mass of glucose, 0.05 to 0.75 parts by mass of N-acetylgalactosamine, 0.1 to 1.5 parts by mass of N-acetylglucosamine, 0.1 to 0.75 parts by mass of mannose, 0.01 to 0.45 parts by mass of fucose, and 0.005 to 0.15 parts by mass of N-acetylneuraminic acid.

[0019] As will be explained later with reference to experimental results, such a combination can effectively produce anti-aging effects and immune function improving effects.

[0020] Additionally, it can be said that the present invention provides a method for using the composition comprising the liposome encapsulating the above-mentioned saccharide as an anti-aging agent and / or an agent for improving immune function.

[0021] The functional food according to this embodiment contains the anti-aging composition according to this embodiment in an amount of 1.665 to 91.85 parts by mass per 100 parts by mass.

[0022] Here, functional foods is a concept that encompasses all foods that do not contain pharmaceutical ingredients and are said to contribute to the maintenance and promotion of health, and includes, for example, nutritional supplements, health supplements, nutritionally adjusted foods, as well as general foods such as so-called supplements, and health functional foods such as foods for specified health uses, nutritional functional foods, and foods with functional claims.

[0023] Furthermore, the dosage form is not particularly limited, and any dosage form can be selected, such as tablets, capsules, fine granules, pills, lozenges, liquids, and jellies.

[0024] In addition, when used in the functional food according to the present embodiment, the amount of the anti-aging composition according to the present embodiment added can be adjusted appropriately depending on the application. Specifically, the anti-aging composition according to the present embodiment can be used as it is as a functional food, or raw materials for auxiliary purposes such as preparation of dosage form can be further added. For example, the anti-aging composition according to the present embodiment can be contained in an amount of 1.665 to 100 parts by mass, more specifically 1.665 to 91.85 parts by mass, per 100 parts by mass of the functional food, to obtain a remarkable anti-aging effect.

[0025] Hereinafter, the anti-aging action of the anti-aging composition according to this embodiment will be described with reference to the results of each experiment.

[0026] 1. Preparation of Anti-Aging Composition First, the anti-aging composition according to the present embodiment was prepared using lecithin as an emulsifying component and various sugars as water-soluble components.

[0027] 4 g of lecithin as an emulsifying component and 36 g of ethanol as a dissolving agent were weighed out into a 100 ml beaker, and stirred with a stirrer to prepare 40 g of a 10 w / w % lecithin-ethanol solution.

[0028] Next, 0.3 g of galactose, 10.8 g of xylooligosaccharide containing 90 to 100% by mass of xylose, 0.9 g of glucose, 1.72 g of shark cartilage extract containing 15 to 40% by mass of N-acetylgalactosamine, 0.92 g of N-acetylglucosamine, 0.9 g of aloe vera leaf juice powder containing 30 to 50% by mass of mannose, 0.56 g of mozuku extract containing 25 to 45% by mass of fucose, and 1.38 g of bird's nest containing 0.5 to 5% by mass of N-acetylneuraminic acid were weighed into a 100 ml beaker, and 78.52 g of purified water was added and dissolved to prepare 96 g of a sugar aqueous solution.

[0029] Next, a 2000 ml recovery flask into which 40 g of lecithin-ethanol solution had been dispensed was placed in an evaporator, a water bath was set to 40°C, and the pressure inside the recovery flask was reduced to approximately 40 hPa, and the ethanol removal process was carried out for 30 minutes.

[0030] The recovery flask was then removed from the evaporator, and the prepared sugar aqueous solution was added and emulsified to prepare 100 g of sugar liposomes, which was used as the anti-aging composition containing a sugar incorporated into a liposome according to this embodiment.

[0031] 2. SA-β-gal activity inhibition evaluation test The evaluation of the inhibitory effect of β-galactosidase activity is considered to be the simplest and most sensitive indicator of cellular senescence. It is known that SA-β-Gal activity (senescence-associated beta-galactosidase) in human skin fibroblasts increases with cell passage and with the age of the subjects from whom the cells were collected.

[0032] Therefore, it is possible to evaluate the inhibition of cellular senescence, i.e., cellular anti-aging, by evaluating the inhibition of SA-β-Gal activity. SA-β-gal activity is also used as an index of cellular senescence in many aging studies.

[0033] Here, to evaluate SA-β-gal activity, normal human skin senescent fibroblast cells were cultured with the test sample added, and the SA-β-gal activity was calculated from the fluorescence intensity (Ex. 535 nm / Em. 580 nm) using the Cellular Senescence Plate Assay Kit - SPiDER-βGal (Dojindo Laboratories, Ltd.) according to existing protocols.

[0034] Aged normal human skin fibroblast senescent cells (senescent cells) were prepared by adding 1% penicillin to DMEM medium as the basal medium (DMEM (-)) and adding 10% FBS to the basal medium (DMEM (+)) as the culture medium. Normal human skin fibroblasts (PromoCell GmbH, C-12302) were subcultured in the culture medium (DMEM (+)) for approximately 3 months to produce senescent cells.

[0035] The senescent cells were exposed to the test samples by preparing the test samples in culture medium (DMEM (+)) at 0 (control), 0.01, 0.1, and 1.0 (w / v) %, providing them to normal human skin fibroblast senescent cells that had been synchronously cultured in basal medium (DMEM (-)) at 37°C for 24 hours, and then culturing them at 37°C for 72 hours. The test results are shown in Figure 1.

[0036] (a. Evaluation test of SA-β-gal activity inhibition of anti-aging composition) In Fig. 1, Young refers to relatively young cells with a passage number of 19, and Control refers to relatively aged cells with a passage number of 29. Rapamycin is a substance known to have an anti-aging effect, and the liposomal saccharide mixture is the anti-aging composition according to this embodiment, and the saccharide mixture is a mixture prepared in a manner substantially similar to that of the anti-aging composition according to this embodiment, except that no lecithin was used and liposome formation was not performed.

[0037] As can be seen from FIG. 1, significant inhibition of SA-β-gal activity was confirmed in all of the rapamycin-added sample, the sugar mixture, and the anti-aging composition compared to the control.

[0038] Furthermore, it was confirmed that the anti-aging composition significantly inhibited SA-β-gal activity against the sugar mixture.

[0039] (b. SA-β-gal activity inhibition evaluation test of each sugar) Next, the SA-β-gal activity suppression effect was compared between the case where the anti-aging composition according to the present embodiment was added and the case where each sugar used as a raw material of the anti-aging composition was added alone. The test results are shown in Figure 2.

[0040] As can be seen from FIG. 2, it was shown that SA-β-gal activity was suppressed when the anti-aging composition according to this embodiment was added compared to when any of the saccharides were used alone.

[0041] [3. Evaluation of aging-related gene expression] Next, we evaluated the expression levels of the aging-related genes p21 and p53. p21 is one of the most established aging markers, and is a gene that not only stops the cell cycle, but also inhibits apoptosis and promotes aging. In addition, p53 is suggested to act as an important signal molecule for cellular aging, and is also involved in the pathology of age-related diseases.

[0042] Here, the amount of mRNA of the aging-related genes p21 and p53 was quantified by real-time PCR. Figure 3 shows the results of the mRNA quantification.

[0043] First, as shown in Figure 3(a), for the aging-related gene p21, both the sugar mixture and the anti-aging composition showed a significant (p<0.05) decrease in expression level compared to aging cells (control) with passage number 34. Furthermore, when comparing the sugar mixture and the anti-aging composition, the anti-aging composition showed a lower value.

[0044] Furthermore, as shown in Figure 3(b), a significant (p<0.05) decrease in expression level of the aging-related gene p53 was confirmed in both the sugar mixture and the anti-aging composition compared to aging cells at passage number 39 (control).

[0045] [4. Intracellular NAD + Quantitative evaluation test Next, intracellular NAD + The amount of NAD was evaluated. + is one of the cofactors for the energy production reaction in mitochondria and acts as a NAD + It is known that the amount of

[0046] Here, the amount of intracellular NAD / NADH was calculated from the absorbance (450 nm) using an NAD / NADH measurement kit (Dojindo Laboratories, Ltd.) according to the existing protocol. + The quantitative results are shown.

[0047] As shown in FIG. 4, both the sugar mixture and the anti-aging composition significantly (p<0.05) reduced intracellular NAD in senescent cells at passage number 33 (control). + In addition, when comparing the sugar mixture with the anti-aging composition, the anti-aging composition significantly (p<0.05) increased the amount of intracellular NAD + The amount of was increasing.

[0048] [5. Evaluation of intracellular ATP content] Next, an evaluation test was conducted on the amount of intracellular ATP. ATP is the source of energy produced in mitochondria, and it is known that the amount of ATP produced decreases with aging.

[0049] Here, the amount of intracellular ATP was measured from the amount of luminescence using the ATP Assay Kit-Luminescence (Dojindo Laboratories, Ltd.) according to existing protocols. Figure 5 shows the results of measuring intracellular ATP.

[0050] As shown in Figure 5, the sugar mixture showed almost no change compared to senescent cells (control) with passage number 33, but the anti-aging composition showed a significant (p<0.05) increase in intracellular ATP. In addition, when comparing the sugar mixture with the anti-aging composition, the amount of intracellular ATP was significantly (p<0.05) increased with the anti-aging composition.

[0051] [6. Summary of Anti-Aging Related Evaluation Tests] As mentioned above, [2. SA-β-gal activity inhibition evaluation test], [3. Aging-related gene expression evaluation test], and [4. Intracellular NAD + From the results of each of the anti-aging-related evaluation tests, {5. Intracellular ATP Amount Evaluation Test} and {5. Intracellular ATP Amount Evaluation Test}, it was shown that the anti-aging composition according to this embodiment has an excellent anti-aging effect.

[0052] [7. Evaluation of immune function improvement effect] Next, in order to evaluate the immune function improving effect of the anti-aging composition according to this embodiment, the effect on macrophages was examined.

[0053] (a. Macrophage phagocytic activity test) First, in order to confirm the effect of the anti-aging composition according to this embodiment on immune function, a test was conducted as to whether the anti-aging composition according to this embodiment activates macrophage phagocytosis.

[0054] First, 1 x 10 RAW264.7 cells were cultured. 5 The cells / well were seeded onto a 96-well plate and incubated overnight at 37°C.

[0055] Next, the thoroughly vortexed anti-aging composition was diluted with a medium to 1 w / v%, and filtered through a 0.2 μm filter to obtain the filtrate as a 1 w / v% test sample. Similarly, the 1 w / v% test sample was further serially diluted with a medium to prepare 0.1 w / v% and 0.01 w / v% test samples.

[0056] The supernatants were then removed from the 96-well plates, and 100 μL of each of these samples was added to the cells and incubated at 37° C. for 3 hours.

[0057] Next, 10 μL of FITC-latex-beads (Cayman, Catalog No. 400291) were diluted with 300 μL of medium and added at 10 μL per well, and the plate was incubated at 37° C. overnight.

[0058] Next, the medium was removed, 100 μL of methanol was added, and methanol fixation was performed. After removing the methanol, the cells were washed with PBS and observed under a fluorescent microscope at λex=485 nm and λem=535 nm.

[0059] As a result, as shown in the graph of FIG. 6, no improvement in the phagocytic activity of uninduced macrophage cells was confirmed at any concentration of the anti-aging composition according to this embodiment.

[0060] (b. Microarray Testing) Next, microarray analysis was carried out to confirm what gene group the anti-aging composition according to this embodiment affects.

[0061] First, 6 × 10 RAW264.7 cells were cultured. 6 The cells were seeded at 100 cells / well onto a 6φ petri dish and incubated overnight at 37°C.

[0062] Next, the thoroughly vortexed anti-aging composition was diluted with the medium to 1 w / v % and filtered through a 0.2 μm filter, and the filtrate was used as a 1 w / v % test sample.

[0063] Next, the supernatant was removed from the 6φ Petri dishes, and 5 mL of these samples was added to the cells and incubated at 37° C. for 24 hours.

[0064] Next, the supernatant was removed, the cells were collected with a cell scraper, washed with PBS, centrifuged at 600×g for 5 minutes, and RNA was collected with Nucleo Spin RNA. The absorbance of the extracted RNA was measured at 260 nm using a spectrophotometer to determine the amount and purity of nucleic acid.

[0065] The collected RNA was subjected to an outsourced DNA array test (Filgen Corporation, Clariom S Assay Mouse contract analysis). This assay was performed using a DNA chip equipped with more than 20,000 genes with known functions. The results were analyzed using the dedicated analysis software "Microarray Data Analysis Tool."

[0066] As a result, an increase in the expression level of genes related to inflammatory macrophages (M1) (inflammatory-promoting immune activity) was confirmed.

[0067] (c. Evaluation of the effect of anti-aging compositions on anti-inflammatory induced macrophages) Since an increase in the expression level of inflammatory cytokine genes was confirmed in the above-mentioned microarray test, an attempt was made to evaluate the effect of administering the anti-aging composition according to this embodiment after inducing macrophages to be anti-inflammatory (M2).

[0068] First, 8 × 10 RAW264.7 cells were cultured. 5 The cells / well were seeded onto a 6-well plate and incubated overnight at 37°C.

[0069] Next, 4 μL each of 0.1 μg / μL IL-4 and IL-13 (M2 macrophage-inducing factor) was placed in the same tube, and medium was added thereto so that the concentration became 20 ng / mL.

[0070] Next, the supernatant from the plate was removed, and 3 mL of medium containing IL-4 and IL-13 (M2 macrophage-inducing factors) at 20 ng / mL each was added to each well, followed by incubation at 37° C. for 72 hours.

[0071] Next, the thoroughly vortexed anti-aging composition was diluted with the medium to 1 w / v % and filtered through a 0.2 μm filter, and the filtrate was used as a 1 w / v % test sample.

[0072] Next, the supernatant was removed from the plate, and 3 mL of 1 w / v % test sample was added to each well, followed by incubation at 37° C. for 24 hours.

[0073] Next, the cells were harvested, centrifuged, the supernatant was removed, and the cells were washed with PBS. RNA was harvested using Nucleo Spin RNA. cDNA was synthesized and used to perform quantitative PCR for TNFα, IL-1β, and CD206. TNFα and IL-1β are genes highly expressed in inflammatory macrophages, and CD206 is a gene highly expressed in anti-inflammatory macrophages.

[0074] As a result, as shown in Figure 7(a), a significant increase in TNFα, an inflammatory cytokine, was confirmed. In addition, as shown in Figure 7(b), an increase in IL-1β was also confirmed by adding the anti-aging composition according to the present embodiment, although it was not significant. Meanwhile, as shown in Figure 7(c), data was obtained showing that the anti-inflammatory marker CD206 was decreased.

[0075] These results indicate that the anti-aging composition according to the present embodiment has an immune function improving effect, more specifically, an activity of inducing M2 macrophages to M1 macrophages (converting anti-inflammatory induced macrophages into inflammatory macrophages).

[0076] [8. Examples of Functional Food Manufacturing] Next, a functional food containing the anti-aging composition according to the present embodiment was produced. As an example, a gel-type functional food was produced.

[0077] Specifically, first, 57.44 g of the anti-aging composition prepared in the same manner as in [1. Preparation of anti-aging composition] was dispensed into a 200 mL beaker.

[0078] Next, 0.65 g of thickening polysaccharide, 0.4 g of dietary fiber, 5.3 g of lactose, 4 g of glucose, 0.2 g of acidulant, and 1 g of sugar cane extract were weighed into a 100 ml beaker, 31.01 g of purified water was added, and the mixture was stirred with a stirrer to prepare 42.56 g of thickening polysaccharide viscous liquid. This was then mixed and stirred with 57.44 g of an anti-aging composition prepared in the same manner as the above-mentioned anti-aging composition to produce functional food A of this embodiment in a gel form.

[0079] Such functional food A is in gel form and can be safely taken orally even by elderly people.

[0080] [9. Effect confirmation test of a comparative composition in which one type of sugar is omitted] The anti-aging composition according to the present embodiment contains eight types of sugars, namely, galactose (Gal), xylose (Xyl), glucose (Glc), N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), mannose (Man), fucose (Fuc), and N-acetylneuraminic acid (NeuAc). An investigation was conducted to determine whether a comparative composition lacking any one of these sugars would be able to exert an anti-aging effect in comparison with control senescent cells, similar to an anti-aging composition containing all of these sugars.

[0081] Eight types of comparative compositions were prepared: a Gal-free comparative composition, a Xyl-free comparative composition, a Glc-free comparative composition, a GalNAc-free comparative composition, a GlcNAc-free comparative composition, a Man-free comparative composition, a Fuc-free comparative composition, and a NeuAc-free comparative composition. For example, the Gal-free comparative composition was prepared according to the above-mentioned [1. Preparation of anti-aging composition], but without using galactose alone. The same was true for the comparative compositions that did not contain other sugars.

[0082] In this section, the SA-β-gal activity inhibition evaluation test was also used as an index for confirming the anti-aging effect. The SA-β-gal activity inhibition evaluation test was performed in the same manner as described above in [2. SA-β-gal activity inhibition evaluation test]. The results are shown in Figure 8. In Figure 8, Young refers to relatively young cells with a passage number of 7, and Control refers to relatively aged cells with a passage number of 37.

[0083] As can be seen from FIG. 8, the comparative composition lacking any one of the saccharides showed no significant difference in inhibition of SA-β-gal activity compared to the control product.

[0084] From this, it was confirmed that the effect of the anti-aging composition of this embodiment is exerted by the mixture of eight types of sugars, and that the effect of inhibiting SA-β-gal activity is reduced if any one type of sugar is missing.

[0085] 10. Dose-effect confirmation test of anti-aging composition Next, four test samples Q1 to Q4 were prepared with the same mixing ratio of the eight sugars but different contents, and a test to confirm the dosage effect of the anti-aging composition by oral ingestion was performed. Each test sample was prepared according to the above-mentioned [1. Preparation of the anti-aging composition], with the composition of each sugar being adjusted to the final concentration shown in Figure 9.

[0086] Each of the test samples Q1 to Q4 was individually packaged at 7 g, and participants were instructed to take one packet per day.

[0087] The test details and schedule are shown in Figure 10. Twelve subjects aged 50 to 65 were divided into four groups of three, A, B, C, and D, and a crossover test was conducted with a four-week intake period and a four-week washout period.

[0088] Additionally, the measurement items were set as anti-aging evaluation indices, which generally decrease with age, including basal metabolism, grip strength, one-legged standing time (with eyes closed), and blood test (sex hormone precursor (DHEA-S)). In addition, NK activity and immunoglobulin (IgA) were set as immune-related evaluation indices.

[0089] Measurements were taken at 0, 4, 8, and 12 weeks, including body weight, body fat, basal metabolism, grip strength, and one-legged standing time (with eyes closed). Blood samples were also taken to measure sex hormone precursors (DHEA-S), natural killer cell activity (NKFlowEx Kit, Exbio Praha as), and immunoglobulin (IgA) in saliva (Secretory Immunglobulin A (sIgA) (IDK sIgA) Kit, Immundiagnostik), and changes were compared before and after intake. NK cell activity was evaluated by measuring CD69, an activation marker for NK cells, using flow cytometry. IgA was measured in saliva using an IgA measurement kit (sandwich ELISA method).

[0090] Figure 11(a) is a graph showing changes in body weight. A tendency for weight to decrease was observed before and after ingestion of all test products, but no significant differences were obtained.

[0091] FIG. 11(b) is a graph showing the change in body fat percentage. From the results of groups A and B, it was confirmed that the intake of test sample Q2 reduced the body fat percentage. From the results of groups C and D, it was confirmed that the intake of test sample Q3 and test sample Q4 reduced the body fat percentage, and the reduction was equivalent to that of test sample Q2. However, no significant difference was confirmed between test sample Q3 and test sample Q4.

[0092] FIG. 11(c) is a graph showing the change in basal metabolic rate. From the results of groups A and B, it was confirmed that basal metabolic rate was increased by taking test sample Q2. Also, from the results of groups C and D, it was confirmed that basal metabolic rate was increased by taking test sample Q3 and test sample Q4, and the increase was equivalent to that of test sample Q2. However, no significant difference was confirmed between test sample Q3 and test sample Q4.

[0093] FIG. 11(d) is a graph showing the change in grip strength. From the results of groups A and B, it was confirmed that grip strength was increased by taking test sample Q2. Also, from the results of groups C and D, a tendency for grip strength to be increased by taking test sample Q3 or test sample Q4 was observed, and the increase was equivalent to that of test sample Q2. However, no significant difference was confirmed between test sample Q3 and test sample Q4.

[0094] FIG. 12(a) is a graph showing the change in one-legged standing time (with eyes closed). From the results of groups A and B, it was confirmed that the ingestion of test sample Q2 extended the one-legged standing time with eyes closed. Furthermore, from the results of groups C and D, it was found that the ingestion of test sample Q3 or test sample Q4 tended to extend the one-legged standing time with eyes closed, and the extension value was equivalent to that of test sample Q2. However, no significant difference was confirmed between test sample Q3 and test sample Q4.

[0095] Figure 12(b) is a graph showing the change in sex hormone precursor (DHEA-S). From the results of groups A and B, it was confirmed that the intake of test sample Q2 increased the amount of DHEA-S compared to the intake of test sample Q1. In addition, from the results of groups C and D, it was found that the intake of test sample Q3 and test sample Q4 tended to increase the amount of DHEA-S, and the value was equivalent to that of test sample Q2.

[0096] Figure 12(c) is a graph showing the change in NK activity. From the results of groups A and B, it was confirmed that taking test sample Q2 improved NK activity compared to taking test sample Q1. Also, from the results of groups C and D, it was found that taking test sample Q3 and test sample Q4 tended to improve NK activity, and the value was equivalent to that of test sample Q2.

[0097] Figure 12(d) is a graph showing changes in immunoglobulin (IgA). From the results of groups A and B, it was confirmed that the ingestion of test sample Q2 increased the IgA concentration in saliva compared to the ingestion of test sample Q1. In addition, from the results of groups C and D, it was observed that the ingestion of test sample Q3 and test sample Q4 tended to increase the IgA concentration in saliva, and the value was equivalent to that of test sample Q2.

[0098] Considering these results, since a significant difference was observed between test sample Q1 (lower limit deviation product) and test sample Q2 (lower limit product) in this test, it was shown that in order to obtain the effects of the anti-aging composition of this embodiment, the daily intake amount needs to be equal to or more than test sample Q2 (7 g per packet).

[0099] Furthermore, since no significant difference was found between test sample Q3 (upper limit product) and test sample Q4 (above the upper limit product), it was considered that the intake amount of test sample Q3 was the proportion of the sugar mixture that afforded the effects of the present invention.

[0100] Furthermore, the results of this example suggest that the anti-aging composition according to this embodiment has the effect of improving biological functions that decline with age and improving immune function.

[0101] As described above, the anti-aging composition according to this embodiment is an anti-aging composition comprising liposomes encapsulating saccharides, the saccharides including 0.1 to 6.75 parts by mass of galactose, 1 to 15 parts by mass of xylose, 0.3 to 16.5 parts by mass of glucose, 0.05 to 0.75 parts by mass of N-acetylgalactosamine, 0.1 to 1.5 parts by mass of N-acetylglucosamine, 0.1 to 0.75 parts by mass of mannose, 0.01 to 0.45 parts by mass of fucose, and 0.005 to 0.15 parts by mass of N-acetylneuraminic acid, and therefore a new anti-aging composition composed of food ingredients can be provided.

[0102] Finally, the above-mentioned embodiments are merely examples of the present invention, and the present invention is not limited to the above-mentioned embodiments. Therefore, even if the above-mentioned embodiments are different, various modifications can be made depending on the design, etc., as long as they do not deviate from the technical idea of ​​the present invention. [Explanation of symbols]

[0103] A Functional food

Claims

1. An anti-aging composition comprising a liposome encapsulating a saccharide, The saccharides include 0.1 to 6.75 parts by mass of galactose, 1 to 15 parts by mass of xylose, 0.3 to 16.5 parts by mass of glucose, 0.05 to 0.75 parts by mass of N-acetylgalactosamine, 0.1 to 1.5 parts by mass of N-acetylglucosamine, 0.1 to 0.75 parts by mass of mannose, 0.01 to 0.45 parts by mass of fucose, and 0.005 to 0.15 parts by mass of N-acetylneuraminic acid, and the anti-aging composition has an immune function improving effect.

2. A functional food comprising the anti-aging composition according to claim 1 in an amount of 1.665 to 91.85 parts by mass per 100 parts by mass.

Images